{
Matthew Weston

People

}
Very Negative
Negative
Neutral
Positive
Very Positive
2025-04-242025-04-242025-04-252025-04-252133221100
Download SVG
Download PNG
Download CSV
Somewhat Relevant
Moderately Relevant
Very Relevant
Highly Relevant
2025-04-242025-04-242025-04-252025-04-252133221100
Download SVG
Download PNG
Download CSV

ubs raises roche price target to 300 francs maintains neutral rating

UBS has increased its price target for Roche from 270 to 300 Swiss francs while maintaining a "Neutral" rating. Analyst Matthew Weston based this adjustment on updated estimates for 2025, with minimal changes to forecasts through 2029.
boerse.de
Swiss Franc Hoffmann-La Roche AG CHE Matthew Weston
Finance & Economy, Market Report
11:21 31.01.2025

ubs raises roche price target to 300 francs maintains neutral rating

UBS has increased its price target for Roche from 270 to 300 francs while maintaining a "Neutral" rating. Analyst Matthew Weston based this adjustment on 2025 estimates, making minimal changes to forecasts through 2029. Roche operates in pharmaceuticals and diagnostics, developing treatments across various disease areas.
MarketScreener
Swiss Franc Roche Holding AG CHE Matthew Weston Show more
Finance & Economy, Market Report
11:09 31.01.2025

ubs maintains buy rating for novartis with price target of 111 francs

UBS has maintained a "Buy" rating for Novartis, setting a price target of 111 francs, following the company's strong performance results. Analyst Matthew Weston highlighted the positive outcomes in a report published on January 31, 2025.
finanzen.at
Swiss Franc Novartis AG UBS AG CHE Matthew Weston
Finance & Economy, Market Report
10:37 31.01.2025

UBS maintains neutral rating for AstraZeneca with target price of 11500 pence

UBS has maintained a "Neutral" rating for AstraZeneca, setting a target price of 11,500 pence. Analyst Matthew Weston noted increased caution among investors in pharmaceutical stocks following Donald Trump's election, despite AstraZeneca's strong growth potential, supported by over ten key studies expected in 2025.
boerse.de
British Pound Sterling AstraZeneca PLC GBR Matthew Weston
Finance & Economy, Market Report
13:01 30.01.2025

UBS maintains neutral rating for Roche with target price of 270 francs

UBS has maintained a "Neutral" rating for Roche, setting a target price of 270 francs. Analyst Matthew Weston noted that the company's fourth-quarter and second-half results met expectations, and he anticipates a similar outlook moving forward.
boerse.de
Swiss Franc Hoffmann-La Roche AG CHE Matthew Weston Hubert Dichtl Thomas Müller Show more
Finance & Economy, Market Report
12:46 30.01.2025

ubs maintains neutral rating for roche with target price of 270 francs

UBS has maintained a "Neutral" rating for Roche, setting a target price of 270 francs. Analyst Matthew Weston noted that the company's fourth-quarter results and outlook met expectations, reflecting stability in performance.
finanzen.at
Swiss Franc Hoffmann-La Roche AG UBS AG CHE Matthew Weston
Finance & Economy, Market Report
11:46 30.01.2025

ubs raises price target for sartorius stedim biotech while maintaining neutral rating

UBS has increased its price target for Sartorius Stedim Biotech from 222 to 244 euros following strong preliminary quarterly results, while maintaining a "Neutral" rating. Analyst Matthew Weston noted signs of growth and a conservative outlook for 2025 after previous target reductions. Estimates for 2025 to 2029 have also been raised.
boerse.de
Euro Sartorius Stedim Biotech S.A. FRA CHE Matthew Weston
Finance & Economy, Market Report
08:34 29.01.2025

ubs raises price target for sartorius while maintaining neutral rating

UBS has increased its price target for Sartorius from 280 to 302 euros following strong preliminary quarterly results, while maintaining a "Neutral" rating. Analyst Matthew Weston noted signs of growth and acknowledged management's conservative outlook for 2025 after previous target reductions. Estimates for 2025 to 2029 have also been raised.
boerse.de
Euro SARTORIUS CHE Matthew Weston
Finance & Economy, Market Report
08:28 29.01.2025

ubs raises target price for sartorius stedim biotech to 244 euros

UBS has increased its target price for Sartorius Stedim Biotech from 222 to 244 euros following strong preliminary quarterly results, while maintaining a "Neutral" rating. Analyst Matthew Weston noted signs of a return to growth, although management remains conservative in its 2025 outlook after previous target reductions. Estimates for 2025 to 2029 have been raised accordingly.
de.marketscreener.com
Euro Sartorius Stedim Biotech S.A. FRA CHE Matthew Weston
Finance & Economy, Market Report
07:34 29.01.2025

ubs raises target price for sartorius stedim biotech to 244 euros

UBS has increased its target price for Sartorius Stedim Biotech from 222 to 244 euros following strong preliminary quarterly results, while maintaining a "Neutral" rating. Analyst Matthew Weston noted signs of a return to growth, although management remains conservative about the 2025 outlook. Estimates for 2025 to 2029 have been raised accordingly.
aktiencheck.de
Euro Sartorius Stedim Biotech S.A. DEU FRA Matthew Weston
Finance & Economy, Market Report
07:34 29.01.2025
Trending
Subcategory
Corporate News Industry Trends Stock Market Updates Retail and Consumer Goods Global Financial Events Finance Mergers & Acquisitions Global Trade Developments Industry Mergers & Acquisitions Central Bank Actions CEO Changes Banking Regulations Supply Chain Management Startups & Entrepreneurship Energy Sector Developments Government Economic Policies Workplace Trends AI Innovations Cryptocurrency Trends Market Analysis and Predictions Financial Scams and Security
Countries:
USA CHN GBR IND CHE CAN JPN FRA DEU MEX RUS SGP BRA ZAF AUT ARE SAU ITA IDN IRL
Companies:
The Goldman Sachs Group, Inc. Bank of America Corporation Apple Inc. Alphabet Inc. Barclays PLC Tesla, Inc. Wells Fargo & Company Citigroup Inc. Deutsche Bank RV Global PP Commerzbank AG Lloyds Banking Group plc PepsiCo, Inc. BNP Paribas SA Google Inc. NVIDIA Corporation UBS Group AG Wix.com Ltd. BP Castrol K.K. Valvoline Inc. Bosch Limited
Currencies:
United States Dollar Euro Chinese Yuan British Pound Sterling Swiss Franc Indian Rupee Japanese Yen Indonesian Rupiah Canadian Dollar Russian Ruble South Korean Won United Arab Emirates Dirham Offshore Chinese Yuan Ghanaian Cedi Hungarian Forint Albanian Lek Brazilian Real Singapore Dollar Qatari Riyal Jordanian Dinar
People:
Donald Trump Elon Musk Warren Buffett Sergey Brin Larry Page Goldman Sachs Kelvin Taylor Carsten Fritsch Christopher Chandler Scott Bessent Martin Schlegel Jerome Powell Kubra Khan Joe Biden Volkmar Baur Christopher Wallerstedt Brian Moynihan Airlangga Hartarto Francesco Gaetano Caltagirone Leonardo Del Vecchio

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.